Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.41 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25482830 | 0.81 | L3MBTL3 (0.45) | CRBNRIPK1NPC1L1HPGDACHE | |
| SCHEMBL25188224 | 0.81 | L3MBTL3 (0.45) | CRBNRIPK1NPC1L1HPGDACHE | |
| SCHEMBL25485315 | 0.79 | CRBN (0.40) | CRBNRIPK1NPC1L1HPGDALDH1A1 | |
| SCHEMBL25190327 | 0.78 | CRBN (0.40) | CRBNRIPK1NPC1L1HPGDALDH1A1 | |
| SCHEMBL25483631 | 0.78 | RIPK1 (0.46) | CRBNRIPK1HPGDALDH1A1HTT | |
| SCHEMBL25484384 | 0.78 | RIPK1 (0.46) | CRBNRIPK1HPGDALDH1A1HTT | |
| SCHEMBL25482881 | 0.74 | HSD11B1 (0.48) | RIPK1NPC1L1ALDH1A1ACHEL3MBTL1 | |
| SCHEMBL25484457 | 0.74 | ACHE (0.43) | CRBNRIPK1NPC1L1ALDH1A1ACHE | |
| SCHEMBL25483806 | 0.74 | HSD11B1 (0.48) | RIPK1NPC1L1ALDH1A1ACHEL3MBTL1 | |
| SCHEMBL25483735 | 0.74 | ACHE (0.43) | CRBNRIPK1NPC1L1ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | RIPK1, RIPK3, RIPK4 | CRBN 4505/4885RIPK1 1/4885NPC1L1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.